Stock Markets March 4, 2026

UBS Cuts Syensqo Rating and Target, Citing Weakness in Specialty Polymers

Analyst downgrade follows disappointing Q4 2025 specialty polymers performance and prompts reductions to medium-term forecasts

By Nina Shah
UBS Cuts Syensqo Rating and Target, Citing Weakness in Specialty Polymers

UBS lowered its rating on Syensqo from Buy to Neutral and trimmed its price target to €54 from €81 after the company's fourth-quarter 2025 report showed a sharp organic sales drop in Specialty Polymers. The bank reduced 2026-2028 EBITDA and EPS forecasts, citing volume and pricing pressures, and projects a modest sales decline and EBITDA roughly in line with management guidance for 2026.

Key Points

  • UBS downgraded Syensqo from Buy to Neutral and cut its price target to €54 from €81, following Q4 2025 results.
  • Specialty Polymers organic sales fell 13% year-over-year in Q4 2025, with UBS estimating volumes down 11% and prices down 2%; the segment makes up roughly 40% of group sales.
  • UBS trimmed 2026-2028 EBITDA forecasts by about 13% per year and lowered EPS estimates by 27% annually; it now forecasts group sales to decline 3.5% in 2026 and 2026 EBITDA of €1,088 million, roughly in line with management guidance.

UBS downgraded Syensqo shares (EURONEXT:SYENS) to Neutral from Buy and decreased its price target to €54 from €81 following the company’s fourth-quarter 2025 results, the bank said on Tuesday. The move reflects mounting uncertainty about the timing and strength of an earnings recovery in Syensqo’s Specialty Polymers division.

In the quarter, Syensqo reported organic sales in Specialty Polymers were down 13% year-over-year. UBS said the decline was driven by weaker volumes in electronics end markets and pricing pressures in automotive applications. The research house estimated that volumes in the segment fell 11% in the period while prices slipped 2%.

Specialty Polymers represents about 40% of Syensqo’s total sales, making its performance a material influence on the group’s near-term outlook. In response to the Q4 print, UBS reduced its 2026-2028 EBITDA forecasts by an average of 13% per year and cut EPS estimates by roughly 27% per year.

For 2026, UBS now expects group sales to decline 3.5%. The bank breaks that figure down into a 2% volume decrease, a 0.5% price decline and a 1.5% foreign exchange headwind. UBS’s updated forecast for 2026 EBITDA is €1,088 million, which it notes is broadly in line with Syensqo’s management guidance of around €1.1 billion.

UBS highlighted that Syensqo’s Specialty Polymers business has lagged peers on organic sales growth since the second quarter of 2024, with the divergence widening in the fourth quarter of 2025. While Syensqo’s Specialty Polymers volumes fell an estimated 11% in Q4, specialty chemical peers reported volumes up 2% and prices up 1% in the same period, according to UBS.

The bank derived its €54 price target as the average of two valuation approaches: a discounted cash flow valuation of €52 and a sum-of-the-parts valuation of €56. UBS also pointed to an expected average free cash flow yield of about 6% over the next three years as a factor that should provide some support to the shares.

On valuation metrics, Syensqo is projected to trade at a 2026 EV/EBITDA multiple of roughly 6.7 times, which UBS describes as approximately a 35% discount to peers. The combination of weaker near-term operational performance and the reduction in medium-term earnings forecasts underpins the firm’s decision to move the rating to Neutral and lower the price target.


Context for markets: The revision from UBS is focused on the chemicals and specialty materials sector, with particular implications for companies exposed to electronics and automotive end markets where volumes and pricing have proven volatile.

Risks

  • Uncertainty over the timing and strength of an earnings recovery in Specialty Polymers, which materially affects Syensqo given the segment’s ~40% share of sales - impacts specialty chemicals and materials sectors.
  • Foreign exchange headwinds that UBS quantifies as a 1.5% negative impact to 2026 sales - relevant for multinational chemical producers with cross-currency exposure.
  • Continued underperformance versus specialty chemical peers on organic sales growth, which could pressure relative valuation and investor sentiment in the chemicals sector.

More from Stock Markets

Rising oil and gas costs heighten margin pressure for European chemical firms, JPMorgan says Mar 4, 2026 VCI Global Stock Jumps After Launch of Malaysia’s First NVIDIA-Powered AI GPU Center Mar 4, 2026 CoreWeave Shares Tick Up After Perplexity Names It As Inference Cloud Partner Mar 4, 2026 SCHMID Group Shares Rally After First Delivery of Null Line H+ Panel-Level Packaging System Mar 4, 2026 Premarket Rally Sees Nvidia, Moderna and CrowdStrike Move Higher While Abercrombie Stocks Slip Mar 4, 2026